Indivi

Switzerland
Breíl, Grisons, Switzerland, 4001

Company profile

Indivi company profile

Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotyping instruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Postal code
4001
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
9
Total equity funding
$20M
Last funding
Series Unknown / $18.8M / 2025-11-12
Last equity funding
Series Unknown / $18.8M
Investors
3
Lead investors
1
Founders
3
Articles
38

Founders and investors

Founders

Corne de JongGuilhem DupontJose Santos

Lead investors

Ava Investors

Investors

Ava InvestorsLichtsteiner FoundationZühlke Ventures AG